74 articles in this topic
A completed clinical trial tests which dietary approach best controls extreme triglyceride levels in multifactorial chylomicronemia patients.
A Phase 1 trial tests whether lowering compensatory hyperinsulinemia with diazoxide improves glucose and lipid metabolism in NAFLD patients.
A sponsored 90-day trial of enhanced-absorption quercetin targeting cholesterol, blood sugar, and metabolic age was terminated before completion.
A Phase 2 trial tests a GalNAc-conjugated antisense therapy in familial partial lipodystrophy patients with dangerously high triglycerides.
A completed trial investigates whether replenishing glutathione precursors can reverse metabolic dysfunction in elderly adults.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
A completed Maastricht trial tests whether targeted protein and exercise can boost muscle protein synthesis before dialysis becomes necessary.
Phase 4 trial tests whether alirocumab can better control non-HDL cholesterol in high-risk type 2 diabetics failing statin therapy.
Eli Lilly's phase 3 trial pits a novel weekly basal insulin against the gold-standard daily insulin degludec in type 1 diabetes patients.
A completed Danish trial investigates how blocking IL-6 signaling with tocilizumab alters fat, glucose, and protein metabolism in humans.
A Danish case-control trial uses gold-standard metabolic testing to uncover how mtDNA mutations impair muscle glucose uptake and drive insulin resistance.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
